The filing for a mixed shelf offering indicates that BioSig Technologies may issue new securities in the future, which could dilute the value of existing shares. However, it also provides the company with the ability to raise capital as needed, which could support growth initiatives. The short-term impact is likely negative due to the potential for dilution, but the long-term impact could be more positive if the capital is used effectively.